Table 1 Demographic, clinical and neuropsychological characteristics of: (A) discovery sample; (B) validation clinical sample; (C) validation familial risk sampl

A. Discovery sample

N

105

71

34

n.a

Gender Ratio (M/F)

58/47

35/36

23/11

0.119

Age

31.96 ± 10.14

28.82 ± 6.43

38.53 ± 13.05

 < 0.001*

Socio-economic Status

40.58 ± 17.01

40.77 ± 17.61

40.18 ± 15.94

0.867

WAIS IQ

105.77 ± 15.97

111.04 ± 10.93

94.76 ± 19.13

 < 0.001*

Premorbid IQ

114.27 ± 5.62

116.40 ± 2.69

109.80 ± 7.33

 < 0.001*

GAF total score

51.79 ± 15.72

n.a

51.79 ± 15.72

n.a

Chlorpromazine eq

174.60 ± 110.13

n.a

174.60 ± 110.13

n.a

B. Validation clinical sample

N

90

60

30

n.a

Gender ratio (M/F)

35/55

17/43

18/12

0.007*

Age

23.04 ± 6.33

22.95 ± 6.27

23.23 ± 6.56

0.843

Socio-Economic Status

42.62 ± 14.50

43.81 ± 14.78

40.25 ± 13.87

0.275

WAIS IQ

105.41 ± 11.26

106.60 ± 10.44

103.03 ± 12.61

0.158

Premorbid IQ

114.28 ± 3.55

115.33 ± 2.49

112.19 ± 4.39

0.300

GAF total score

64.04 ± 15.03

n.a

64.22 ± 15.34

n.a

Chlorpromazine eq

91.67 ± 46.87

n.a

95.45 ± 47.19

n.a

C. Validation familial risk sample

N

39

26

13

n.a

Gender Ratio (M/F)

15/24

10/16

5/8

0.727

Age

25.41 ± 7.94

24 ± 5.12

28.23 ± 11.49

0.226

Socio-Economic Status

40.68 ± 13.50

38.19 ± 14.13

45.65 ± 10.99

0.105

WAIS IQ

108.13 ± 12.73

107.50 ± 13.71

109.38 ± 10.90

0.669

Premorbid IQ

115.70 ± 3.29

114.82 ± 3.01

117.46 ± 3.22

0.016*